← 返回专利悬崖列表




溴化甲基纳曲酮
Tier C · 观察 / 贸易Methylnaltrexone Bromide
Progenics Pharmaceuticals Inc
原研
2008
首批上市
-
到期年(公开口径)
$0.11B ▲
峰值销售
化学药
类型
靶点:MOR1
商品名:Relistor
适应症(已批准):阿片类依赖、便秘、阿片类药物引起的便秘
各地区研发/上市状态
美国
批准上市
2008-04-24
欧盟
批准上市
2008-07-01
中国
临床一期
2023-12-15
日本
-
合成路线与中间体5 routes
原研路线 × 1优化路线(非专利)× 4工艺路线 × 0
路线按「原研路线 → 优化路线 / 工艺路线(非专利)」排序。每条路线附本站自绘的路线流程图(中间体 → 原料药)与中间体表(编号 / CAS / 英文名),可直接用于供应商开发与询价。流程图由本站依据已授权的结构化数据自行渲染,未使用任何第三方路线图。
原研Route 1步骤 1 · 总收率 45 g

| 编号 | CAS 号 | 中间体名称 |
|---|---|---|
| METHB-001 | 16590-41-3 | (4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,3,4,4a,5,6-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7(7aH)-one |
优化Route 2步骤 4 · 总收率 22.5 g

| 编号 | CAS 号 | 中间体名称 |
|---|---|---|
| METHB-001 | 16590-41-3 | (4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,3,4,4a,5,6-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7(7aH)-one |
| METHB-002 | 33522-95-1 | (4R,4aS,7aR,12bS)-4a,9-dihydroxy-2,3,4,4a,5,6-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7(7aH)-one |
| METHB-003 | 7051-34-5 | (bromomethyl)cyclopropane |
| METHB-004 | 836602-51-8 | (4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a-hydroxy-7-oxo-2,3,4,4a,5,6,7,7a-octahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-9-yl ethyl carbonate |
| METHB-005 | 1082510-80-2 | (3S,4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-9-((ethoxycarbonyl)oxy)-4a-hydroxy-3-methyl-7-oxo-2,3,4,4a,5,6,7,7a-octahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-3-ium methyl sulfate |
优化Route 3步骤 5 · 总收率 4.3 g

| 编号 | CAS 号 | 中间体名称 |
|---|---|---|
| METHB-001 | 16590-41-3 | (4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,3,4,4a,5,6-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7(7aH)-one |
| METHB-003 | 7051-34-5 | (bromomethyl)cyclopropane |
| METHB-006 | 52446-24-9 | (4R,4aS,7aR,12bS)-4a,9-dihydroxy-2,3,4,4a,5,6-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7(7aH)-one hydrochloride |
| METHB-007 | 153567-11-4 | (4R,4aS,7aR,12bS)-9-(benzyloxy)-3-(cyclopropylmethyl)-4a-hydroxy-2,3,4,4a,5,6-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7(7aH)-one |
| METHB-008 | 1013912-16-7 | (3S,4R,4aS,7aR,12bS)-9-(benzyloxy)-3-(cyclopropylmethyl)-4a-hydroxy-3-methyl-7-oxo-2,3,4,4a,5,6,7,7a-octahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-3-ium methyl sulfate |
| METHB-009 | 1013912-02-1 | (3S,4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-3-methyl-7-oxo-2,3,4,4a,5,6,7,7a-octahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-3-ium methyl sulfate |
优化Route 4步骤 3 · 总收率 74.2 g

| 编号 | CAS 号 | 中间体名称 |
|---|---|---|
| METHB-001 | 16590-41-3 | (4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,3,4,4a,5,6-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7(7aH)-one |
| METHB-010 | 96453-52-0 | (4R,4aS,7aR,12bS)-9-((tert-butyldimethylsilyl)oxy)-3-(cyclopropylmethyl)-4a-hydroxy-2,3,4,4a,5,6-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7(7aH)-one |
| METHB-011 | 1250269-27-2 | (3S,4R,4aS,7aR,12bS)-9-((tert-butyldimethylsilyl)oxy)-3-(cyclopropylmethyl)-4a-hydroxy-3-methyl-7-oxo-2,3,4,4a,5,6,7,7a-octahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-3-ium carbonate |
优化Route 5步骤 3 · 总收率 5.2 g

| 编号 | CAS 号 | 中间体名称 |
|---|---|---|
| METHB-001 | 16590-41-3 | (4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a,9-dihydroxy-2,3,4,4a,5,6-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7(7aH)-one |
| METHB-012 | 92398-33-9 | (4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a-hydroxy-9-((2-(trimethylsilyl)ethoxy)methoxy)-2,3,4,4a,5,6-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-7(7aH)-one |
| METHB-013 | 1446094-54-7 | (3S,4R,4aS,7aR,12bS)-3-(cyclopropylmethyl)-4a-hydroxy-3-methyl-7-oxo-9-((2-(trimethylsilyl)ethoxy)methoxy)-2,3,4,4a,5,6,7,7a-octahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-3-ium iodide |
常见问题(FAQ)
溴化甲基纳曲酮的适应症有哪些?
已批准的适应症包括:阿片类依赖、便秘、阿片类药物引起的便秘。
溴化甲基纳曲酮的专利什么时候到期?
溴化甲基纳曲酮的专利到期年暂无公开口径,本页会在数据管道核实后更新。
溴化甲基纳曲酮有几条合成路线?
本站收录 5 条合成路线,最短路线 1 步、总收率 45 g。每条路线的中间体均带登记编号与 CAS 号。
溴化甲基纳曲酮的关键中间体在哪里可以采购?
溴化甲基纳曲酮路线中的中间体均已建立 CAS 档案,可直接按 CAS 发起询价,需求会进入供应网络撮合池。
如何获取溴化甲基纳曲酮中间体的报价?
在本页选择目标中间体的 CAS 进入档案页,或在询价页直接提交需求;CAS 会自动带入供需撮合流程,由供应网络反馈报价。
数据来源:多源数据交叉核实(仅结构化字段) · 2026-09-24